Susanne Malander

Skåne University Hospital
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Background Ovarian cancer is often diagnosed in advanced stages, resulting in poor outcomes. There is an unmet need for a sensitive and specific screening tool for early-stage detection of ovarian cancer. Methods Recognizing that high-grade serous ovarian carcinoma (HGSC) is driven by copy number alterations (CNAs) and that tumor DNA can be detected in cervical samples, we analyzed CNAs from shallow whole genome sequencing of 212 cervical samples from 128 women with/without HGSC, including 29 germline BRCA1/2 mutation carriers. Using a machine-learning classifier, we developed H igh-grade serous ovarian cancer C ervical copy number sig nature (HCsig), a predictor for HGSC detection. Results HGSC-derived CNAs were detectable with HCsig in cervical samples collected several years before diagnosis. Importantly, HCsig correctly identified HGSC in 79% of archival cervical samples, including 91% stage I-II (0-27 months pre-diagnosis), and 77% stage III-IV (0-65 months pre-diagnosis). Among patients with HGSC who had multiple pre-diagnostic samples collected during the pre-symptomatic phase, 85% had at least one HCpositive cervical sample before surgery (up to 65 months before diagnosis). Detection rates were 90% and 76% for BRCA1/2 -mutated and wildtype HGSC, respectively. Validation in 172 independent samples (0-98 months pre-diagnosis) showed 76% sensitivity and 94% specificity (AUC=0.83), including high sensitivity for early-stage cancers. Conclusions We show that applying the HCsig classifier to cervical samples, including from non-symptomatic women several years before diagnosis, holds promise for early-stage detection and secondary prevention of HGSC. Moreover, it may serve as a screening tool to aid decision-making regarding timing of risk-reducing surgery in high-risk populations.

Year:

2025

The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond HRD status remains elusive. This study aims to explore molecular factors that may elucidate why HRD status does not consistently predict PARPi sensitivity. Therefore, we conducted a post hoc translational analysis of formalin-fixed paraffin-embedded tumor samples from the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial (NCT02354131), focusing on alterations pertaining radiologic response and progression-free survival (PFS). DNA sequencing was performed using the TruSight Oncology 500 HT gene panel, with variants classified according to recent guidelines. HRD status had been assessed by Myriad MyChoice CDx. We identified, among 92 patients in the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial, 151 pathogenic or likely pathogenic variants across 81 samples. PARPi-sensitizing variants were found in two out of 10 HRD-negative samples from patients with clinical benefit (PFS ≥12 months), whereas three out of 10 HRD-positive samples from patients having no benefit (PFS ≤6 months) harbored variants associated with PARPi resistance. Additionally, analysis of BRCA1 variants revealed that truncating variants in exon 11 correlated with clinical benefit when niraparib was combined with bevacizumab. Conclusively, our findings highlight the complexity of PARPi response in AOC and underscore the importance of exploring somatic variants beyond HRD status. Further investigation into exon 11 variants of BRCA1 and the potential of combination treatment is warranted. Significance: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

Year:

2025

BRCA1 (top) and BRCA2 (bottom) with variants found in AVANOVA1&2 colored by treatment response (see legend). BRCA1 : Transcript NM_007294.4. In total, 1,863 aa. RING domain (aa 2–101), PALB2 -binding domain (also called coiled-coil domain; aa 1,391–1,424), BRCT repeats (aa 1,650–1857), and exon 11 (aa 224–1,366). BRCA2 : Transcript NM_000059.4. In total, 3,418 aa. PALB2 -binding domain (aa 10–40), DNA-binding domain (aa 2,481–3,186), and exons 10 and 11 (aa 266–2,281).

Year:

2024

Oncoplot showing pathogenic gene alterations. The plot is split into groups by cellular pathways affected by the alteration on the vertical axis and clinical outcome (clinical benefit: PFS ≥12 months, no benefit: PFS ≤6 months) on the horizontal axis. Each column represents one patient. In total, 81 patient samples. See color guide reflecting specific alterations below the plot. # = Reason of “end of treatment” other than progressive disease. Integer “HRD-status and GIS” = the exact GIS reported by MyChoice.

Year:

2024

PFS in months colored by HRD status. Dashed lines at 6 and 12 months illustrate cutoff for “no benefit” and “clinical benefit”. X -axis indicates the number of patients. Reason for end of treatment other than progression: # = toxicity, $ = partial withdrawal of consent (study assessments continued), ¤ = investigator decision, and “…” = no progression at study closure. See guide in plot for color explanations.

Year:

2024

The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond HRD status remains elusive. This study aims to explore molecular factors that may elucidate why HRD status does not consistently predict PARPi sensitivity. Therefore, we conducted a post hoc translational analysis of formalin-fixed paraffin-embedded tumor samples from the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial (NCT02354131), focusing on alterations pertaining radiologic response and progression-free survival (PFS). DNA sequencing was performed using the TruSight Oncology 500 HT gene panel, with variants classified according to recent guidelines. HRD status had been assessed by Myriad MyChoice CDx. We identified, among 92 patients in the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial, 151 pathogenic or likely pathogenic variants across 81 samples. PARPi-sensitizing variants were found in two out of 10 HRD-negative samples from patients with clinical benefit (PFS ≥12 months), whereas three out of 10 HRD-positive samples from patients having no benefit (PFS ≤6 months) harbored variants associated with PARPi resistance. Additionally, analysis of BRCA1 variants revealed that truncating variants in exon 11 correlated with clinical benefit when niraparib was combined with bevacizumab. Conclusively, our findings highlight the complexity of PARPi response in AOC and underscore the importance of exploring somatic variants beyond HRD status. Further investigation into exon 11 variants of BRCA1 and the potential of combination treatment is warranted. Significance: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

Year:

2024

Year:

2022

Collaborators (10)

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Ingrid Hedenfalk

Professor

Lund University

SWEDEN
View details

Sergio Marchini

Head Humanitas Genomic Facility (HuGe)

IRCCS Humanitas Research Hospital

ITALY
View details

Maarit Anttila

Head of the Gyn

Kuopio University Hospital

FINLAND
View details

Sakari Hietanen

Chief of Dept.

Helsinki University Hospital

FINLAND
View details

Line Bjørge

University of Bergen

NORWAY
View details

Maurizio D'Incalci

Head

IRCCS Humanitas Research Hospital

ITALY
View details

Mansoor Mirza

Chief Oncologist

Rigshospitalet

DENMARK
View details

Johanna Mäenpää

Professor

University of Tampere

FINLAND
View details

Srinivas Veerla

Lund University

SWEDEN
View details